WO2005050203A3 - The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis - Google Patents

The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis Download PDF

Info

Publication number
WO2005050203A3
WO2005050203A3 PCT/GB2004/004795 GB2004004795W WO2005050203A3 WO 2005050203 A3 WO2005050203 A3 WO 2005050203A3 GB 2004004795 W GB2004004795 W GB 2004004795W WO 2005050203 A3 WO2005050203 A3 WO 2005050203A3
Authority
WO
WIPO (PCT)
Prior art keywords
ctgf
ctgf receptor
compounds
fibrosis
test sample
Prior art date
Application number
PCT/GB2004/004795
Other languages
French (fr)
Other versions
WO2005050203A2 (en
Inventor
Roger Maxwell Mason
Nadia Abdel Wahab
Original Assignee
Imp College Innovations Ltd
Roger Maxwell Mason
Nadia Abdel Wahab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd, Roger Maxwell Mason, Nadia Abdel Wahab filed Critical Imp College Innovations Ltd
Priority to JP2006540577A priority Critical patent/JP2007515162A/en
Priority to AU2004292013A priority patent/AU2004292013A1/en
Priority to EP04798515A priority patent/EP1718979A2/en
Priority to CA002546401A priority patent/CA2546401A1/en
Publication of WO2005050203A2 publication Critical patent/WO2005050203A2/en
Publication of WO2005050203A3 publication Critical patent/WO2005050203A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention provides a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps: providing a CTGF receptor; providing a test sample; providing a CTGF receptor agonist; exposing the CTGF receptor to the test sample; subsequently or simultaneously exposing the CTGF receptor to the CTGF receptor agonist; detecting and/or measuring the amount of CTGF receptor activation; comparing the amount of CTGF receptor activation detected and/or measured in the presence of the test sample with the amount of CTGF receptor activation detected and/or measured in the absence of a test sample; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF receptor activation. There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds.
PCT/GB2004/004795 2003-11-18 2004-11-15 The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis WO2005050203A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006540577A JP2007515162A (en) 2003-11-18 2004-11-15 Screening method using CTGF and TRKA receptors for the identification of compounds used in the treatment of fibrosis
AU2004292013A AU2004292013A1 (en) 2003-11-18 2004-11-15 Methods for screening using CTGF and TRKA receptor for the identification of compounds for use in treatment of fibrosis
EP04798515A EP1718979A2 (en) 2003-11-18 2004-11-15 Methods of screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
CA002546401A CA2546401A1 (en) 2003-11-18 2004-11-15 The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326780.4A GB0326780D0 (en) 2003-11-18 2003-11-18 Biological materials and uses thereof
GB0326780.4 2003-11-18

Publications (2)

Publication Number Publication Date
WO2005050203A2 WO2005050203A2 (en) 2005-06-02
WO2005050203A3 true WO2005050203A3 (en) 2005-11-17

Family

ID=29763971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004795 WO2005050203A2 (en) 2003-11-18 2004-11-15 The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis

Country Status (7)

Country Link
EP (1) EP1718979A2 (en)
JP (1) JP2007515162A (en)
CN (1) CN1906491A (en)
AU (1) AU2004292013A1 (en)
CA (1) CA2546401A1 (en)
GB (1) GB0326780D0 (en)
WO (1) WO2005050203A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
WO2006102333A2 (en) * 2005-03-21 2006-09-28 Alcon Manufacturing, Ltd. Ophthalmic use of agents which inhibit connective tissue growth factor binding and signalling via the trka/p75ntr receptor complex
MX2011002143A (en) 2008-08-25 2011-07-20 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof.
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP2169059A1 (en) * 2008-09-25 2010-03-31 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for counteracting, preventing and/or determining fibrosis or a risk of fibrosis
EP2221387A1 (en) * 2009-02-19 2010-08-25 Université de la Méditerranée Fibrosis susceptibility gene and uses thereof
HUE044178T4 (en) 2011-02-02 2019-10-28 Excaliard Pharmaceuticals Inc Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
CN107217092A (en) 2011-08-05 2017-09-29 艾克斯-马赛大学 Fibre modification neurological susceptibility IL22RA2 genes and application thereof
KR101467109B1 (en) * 2013-07-10 2014-12-01 영남대학교 산학협력단 Composition for preventing or treating pulmonary fibrosis comprising BIX02189 compound
DK3102555T3 (en) 2014-02-05 2021-08-09 VM Oncology LLC COMPOSITIONS OF THE COMPOUNDS AND USES THEREOF
EP3976657A4 (en) * 2019-05-30 2023-07-05 Sunshine Lake Pharma Co., Ltd. Anti-trka antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, WONG S T ET AL: "Treatment for autonomic dysreflexia using trkA-IgG after spinal cord injury", XP002336070, Database accession no. PREV200100135018 *
LEASK ANDREW ET AL: "Insights into the molecular mechanism of chronic fibrosis: The role of connective tissue growth factor in scleroderma.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 1, January 2004 (2004-01-01), pages 1 - 6, XP008049522, ISSN: 0022-202X *
POLLOCK GRAEME S ET AL: "TrkB receptor signaling regulates developmental death dynamics, but not final number, of retinal ganglion cells.", JOURNAL OF NEUROSCIENCE, vol. 23, no. 31, 5 November 2003 (2003-11-05), pages 10137 - 10145, XP002335976, ISSN: 0270-6474 *
RACHFAL AMY W ET AL: "Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis.", HEPATOLOGY RESEARCH, vol. 26, no. 1, May 2003 (2003-05-01), pages 1 - 9, XP002335977, ISSN: 1386-6346 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 864.4, ISSN: 0190-5295 *
WAHAB NADIA ABDEL ET AL: "Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 16, no. 2, February 2005 (2005-02-01), pages 340 - 351, XP008049530, ISSN: 1046-6673 *

Also Published As

Publication number Publication date
AU2004292013A1 (en) 2005-06-02
GB0326780D0 (en) 2003-12-24
JP2007515162A (en) 2007-06-14
CN1906491A (en) 2007-01-31
EP1718979A2 (en) 2006-11-08
CA2546401A1 (en) 2005-06-02
WO2005050203A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
PL1776587T3 (en) Use of c3a and derivatives thereof as biomarker for colorectal adenoma and/or carcinoma ; diagnosis methods and assays using the same
EP1359417A3 (en) Devices and methods for analyte concentration determination
WO2008041953A3 (en) Dengue diagnosis and treatment
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
WO2003106964A3 (en) High throughput methods and devices for assaying analytes in a fluid sample
WO2005041893A3 (en) Detection of acute myocardial infarction biomarkers
WO2002040998A3 (en) Kit and method for determining multiple analytes
WO2003040728A3 (en) Method and apparatus for the determination of glucose
WO2006036212A3 (en) Non-sugar sweeteners for use in test devices
EP1381864A4 (en) Detection of candida
EP1652676A3 (en) Systems and methods for detecting inkjet defects
WO2005050203A3 (en) The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2003046531A3 (en) Method for detecting defects in substrates
WO2005081783A3 (en) Method for determination and quantification of radiation or genotoxin exposure
WO2005031005A3 (en) Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample
WO2004057341A3 (en) Cvd assay
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2005119209A3 (en) System and method for analyzing microbial growth
WO2007092552A3 (en) Device and methods for detecting and quantifying one or more target agents
WO2008063663A3 (en) Poly (ethylene glycol) anti-body detection assays and kits for performing thereof
WO2003102015A3 (en) Method and apparatus for detecting and monitoring peptides, and peptides identified therewith
EP1586900A3 (en) Methods for identifying combinations of entities as therapeutics
WO2006099537A3 (en) The use of antibody-surrogate antigen systems for detection of analytes
WO2003076896A3 (en) Use of biomarkers to detect breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2546401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 547296

Country of ref document: NZ

Ref document number: 2006540577

Country of ref document: JP

Ref document number: 2827/DELNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004292013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004798515

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004292013

Country of ref document: AU

Date of ref document: 20041115

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004292013

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200480040637.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004798515

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004798515

Country of ref document: EP